Gulf International Bank UK Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 29,850 shares of the biopharmaceutical company’s stock, valued at approximately $3,792,000.
Other institutional investors and hedge funds have also modified their holdings of the company. QS Investors LLC raised its holdings in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $229,000. Fayerweather Charles acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $230,000. Finally, Watch Point Trust Co acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Institutional investors own 88.39% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at $125.25 on Thursday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals, Inc. has a 12-month low of $35.98 and a 12-month high of $147.63. The firm has a market cap of $12,320.00, a price-to-earnings ratio of -23.86 and a beta of 2.98.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same period last year, the company posted ($1.21) earnings per share. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.29 earnings per share for the current year.
In related news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the completion of the sale, the executive vice president now directly owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 274,075 shares of company stock valued at $35,356,089. 4.30% of the stock is owned by corporate insiders.
Several research analysts have weighed in on the company. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a report on Thursday, November 9th. Cowen reiterated a “buy” rating and issued a $151.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, November 9th. Credit Suisse Group boosted their price target on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Finally, JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating in a report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $121.20.
TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/18/gulf-international-bank-uk-ltd-purchases-shares-of-29850-alnylam-pharmaceuticals-inc-alny.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.